Skip to main content

How effective is Tzield?

Medically reviewed by Carmen Pope, BPharm. Last updated on May 3, 2023.

Official answer

by Drugs.com

Tzield has been shown to delay the progression of Stage 2 type 1 diabetes to Stage 3 type 1 diabetes by 25 months (approximately 2 years) in a phase 3, randomized, double-blind clinical trial. In an extended follow-up of this trial (duration 923 days), the average time to diagnosis of stage 3 type 1 diabetes was 59.6 months for Tzield-treated patients compared with 27.1 months for patients given a placebo (a difference of 32.5 months).

Another study that followed people for 7 years found persistent immunological responses and a reduced decline in C-peptide up to 7 years after the diagnosis of diabetes in people who respond to Tzield.

References
  • Herold KC, Bundy BN, Long SA, et al.. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019;381(7):603–613.
  • Hagopian, W., Ferry, R. J., Jr, Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Daifotis, A. G., Herold, K. C., Ludvigsson, J., & Protégé Trial Investigators (2013). Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes, 62(11), 3901–3908. https://doi.org/10.2337/db13-023
  • Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., Herold, K. C., & Type 1 Diabetes TrialNet Study Group (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science translational medicine, 13(583), eabc8980. https://doi.org/10.1126/scitranslmed.abc8980
  • Perdigoto, A. L., Preston-Hurlburt, P., Clark, P., Long, S. A., Linsley, P. S., Harris, K. M., Gitelman, S. E., Greenbaum, C. J., Gottlieb, P. A., Hagopian, W., Woodwyk, A., Dziura, J., Herold, K. C., & Immune Tolerance Network (2019). Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia, 62(4), 655–664. https://doi.org/10.1007/s00125-018-4786-9

Read next

What is Tzeild?

Tzield (teplizumab-mzwv) is an injectable medicine that is used to delay the onset of stage 3 Type 1 diabetes in people whose immune system has begun attacking their insulin-producing cells. Continue reading

How does Tzield work?

Tzield is thought to work by binding to CD3 (a cell surface antigen present on T lymphocytes) to delay the onset of stage 3 type 1 diabetes in adults and children 8 and older with stage 2 type 1 diabetes. Tzield may also deactivate the immune cells that attack insulin-producing cells while increasing the proportion of cells that help moderate the immune response. Tzield is classified as an anti-CD3 monoclonal antibody. Continue reading

How is Tzield administered?

Tzield is given by intravenous infusion over a minimum of 30 minutes once daily for 14 consecutive days. Dosage is based on body surface area and increases. Continue reading

Related medical questions

Drug information

Related support groups